JENNIFER GREENHECK: Open Payments
NPI 1396871158 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,506 in 106 payments from 18 companies in 2025. Trend: 2023 $1,193 · 2024 $5,313 · 2025 $7,506
Consulting: $3,384Food & beverage: $2,941Travel & lodging: $1,181
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 22 | $5,239 |
| AstraZeneca Pharmaceuticals LP | 15 | $526 |
| GlaxoSmithKline, LLC. | 26 | $473 |
| Regeneron Healthcare Solutions, Inc. | 13 | $457 |
| Verona Pharma, Inc. | 8 | $251 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $148 |
| Insmed, Inc. | 4 | $79 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Viatris Specialty LLC | 2 | $43 |
| Calliditas Therapeutics US Inc. | 2 | $41 |
Products named: DUPIXENT, FASENRA, NUCALA, Ohtuvayre, TRELEGY ELLIPTA, BREZTRI, Arikayce, TEZSPIRE.
Industry payments across LA — which companies pay providers there.
